Learning Objectives
- Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
- Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
- Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
- Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
- Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.
- Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
- Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
- Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.
View all episodes
